Projects

Projects per year 2004 2008 2010 2019 2020 2022 2024 2027

• 4 Active
• 22 Finished

Projects per year

Search results

• Active

  OZR4353: OZR opvangmandaat aspirant Vicente Efrain Saavedra Alarcón

  Aerts, J. & Alarcón, V. E. S.

  1/11/24 → 31/10/25

  Project: Fundamental

• IOFPOC60: ESCAPE - Enhanced nanoformulation based on layer-by-layer polyelectrolyte submicroparticles conjugated with cationic peptides

  Aerts, J. & Allard, S.

  1/01/24 → 31/12/25

  Project: Applied

  • Messenger RNA 100%
  • 1-methylpseudouridine 85%
  • Vaccines 81%
  • Nucleosides 80%
  • Nucleoside 70%

• ANI370: In-depth characterization of the dynamics of the functional latent reservoir in long- term cART-treated people living with HIV-1 from Belgium

  Aerts, J. & Allard, S.

  1/01/23 → 31/12/26

  Project: Fundamental

  • Belgium 100%
  • Proviruses 80%
  • HIV 76%
  • HIV-1 64%
  • Acquired Immunodeficiency Syndrome 51%

• SRP86: SRP-Groeifinanciering: Unravelling host-pathogen-immune interactions in infectious diseases: the good, the bad and the ugly

  Allard, S. & Aerts, J.

  1/10/22 → 30/09/27

  Project: Fundamental

  • Communicable Diseases 100%
  • Host-Pathogen Interactions 95%
  • Pandemics 23%
  • Vaccines 21%
  • Allergy and Immunology 15%
• Finished

  OZR4018: OZR backup mandate: The influence of the gut microbiome on mRNA-based HIV-1 vaccination

  Aerts, J. & Cosyns, J.

  1/11/22 → 31/10/23

  Project: Fundamental

  • Gastrointestinal Microbiome 100%
  • Vaccination 70%
  • HIV-1 66%
  • Messenger RNA 50%
  • Viruses 42%

• ANI334: Francqui-Chair VUB - Academic Year 2022-2023: appointed to - Prof. dr. Johan Neyts , KU Leuven

  Aerts, J.

  1/10/22 → 30/09/23

  Project: Fundamental

  • Antiviral Agents 100%
  • Virology 60%
  • Belgium 54%
  • Enterovirus 53%
  • Dengue 53%

• OZR3632: OZR back-ip mandate: Fighting fire with fire: using oncolytic viruses to selectively target complement inhibition in tumor cells in order to alleviate immune suppression

  Vanbellingen, S. & Aerts, J.

  1/11/20 → 31/10/21

  Project: Fundamental

  • Oncolytic Viruses 100%
  • Neoplasms 30%
  • Down-Regulation 11%
  • Complement System Proteins 10%
  • Immunogenic Cell Death 6%

• OZR3633: OZR Back-up mandate: Nanoparticle-encapsulated self-replicating mRNA-based vaccination as a novel therapeutic approach against HIV

  Den Roover, S. & Aerts, J.

  1/11/20 → 31/10/21

  Project: Fundamental

  • Nanoparticles 100%
  • Messenger RNA 96%
  • Vaccination 78%
  • HIV 77%
  • Vaccines 21%

• FWOAL974: Development of a novel nanoparticle formulation for mRNA based therapeutic vaccination

  Aerts, J.

  1/01/20 → 31/12/22

  Project: Fundamental

  • Messenger RNA 100%
  • Caveolae 80%
  • Vaccination 74%
  • Nanoparticles 73%
  • Endocytosis 62%

• FWOSB59: Enhancing the immunogenicity and antitumor efficacy of virotherapy by supplementing an oncolytic virus with checkpoint inhibition and immunological cell death inducers

  Kalus, P., Aerts, J. & Breckpot, K.

  1/01/19 → 31/12/22

  Project: Fundamental

  • Oncolytic Viruses 100%
  • Cell Death 50%
  • Fees and Charges 44%
  • Oncolytic Virotherapy 9%
  • Viral Structures 7%

• ANI210: Towards an integrated immunotherapy approach for advanced melanoma using oncolytic virus therapy, vaccination and immune checkpoint blockade.

  Aerts, J.

  1/01/19 → 30/06/23

  Project: Fundamental

  • talimogene laherparepvec 100%
  • Oncolytic Virotherapy 84%
  • Melanoma 64%
  • Art 63%
  • Contracts 63%

• FWOSB57: Development of a novel nanoparticle formulation for mRNA based therapeutic vaccination against HIV

  D'Haese, S. & Aerts, J.

  1/01/19 → 31/12/22

  Project: Fundamental

  • Nanoparticles 100%
  • Vaccination 90%
  • Fees and Charges 89%
  • Messenger RNA 70%
  • HIV 49%

• OZR3294: Tackling melanoma brain metastases by targeting both sides of the immunological balance: immune stimulation with oncolytic viruses and reversing immune suppression by checkpoint inhibitors

  Aerts, J.

  1/10/18 → 30/09/19

  Project: Fundamental

  • Oncolytic Viruses 100%
  • Melanoma 68%
  • Neoplasm Metastasis 44%
  • Brain 32%
  • Neoplasms 11%

• FWOAL809: Rationally designed therapeutic vaccine against HIV-1 based on a novel formulation of nanoparticle-protected mRNA

  Aerts, J.

  1/01/16 → 31/12/18

  Project: Fundamental

  • Nanoparticles 100%
  • HIV-1 98%
  • Vaccines 84%
  • Messenger RNA 64%
  • Therapeutics 18%

• IWT712: IWT712 In vivo administration of mRNA as a novel vaccination approach for the treatment of HIV-1

  Aerts, J. & Tjok Joe, P. Z. Y.

  1/01/15 → 31/12/18

  Project: Fundamental

  • HIV-1 100%
  • Vaccination 91%
  • Messenger RNA 65%
  • therapeutics 44%
  • Students 40%

• OZR2584: In vivo administration of mRNA as a novel vaccination approach for the treatment of HIV-1.(OZR-Opvangmandaat IWT)

  Aerts, J.

  1/01/14 → 31/12/14

  Project: Fundamental

  • HIV-1 100%
  • Vaccination 91%
  • Messenger RNA 65%
  • Therapeutics 18%

• IWT615: The bidirectional link between tumor angiogenesis and immunity in melanoma brain metastases: potential synergy between anti-angiogenesis and immunotherapy

  Aerts, J.

  1/01/13 → 31/12/16

  Project: Fundamental

  • Melanoma 100%
  • Immunotherapy 70%
  • Neoplasm Metastasis 68%
  • Immunity 65%
  • Brain 56%

• OZR2374: Preklinisch onderzoek naar de interactie tussen tumor angiogenese en immunosuppressie in het kader van de behandeling melanoom hersenmetastasen

  Aerts, J.

  1/10/12 → 31/12/12

  Project: Fundamental

• FWOAL593: iMECHs: Inhibitory MECHanisms exerted by melanoma cells and their environment

  Thielemans, K., Aerts, J. & Breckpot, K.

  1/01/11 → 31/12/14

  Project: Fundamental

  • Neoplasms 100%
  • T-Lymphocytes 38%
  • Antigen-Presenting Cells 21%
  • Myeloid Cells 21%
  • Regulatory T-Lymphocytes 20%

• ADSI259: Research on mechanisms responsible for the functional regulation and accumulation of myeloid diversed supressor cells at melanoma patiënts - Researcher: Sarah Maenhout

  Thielemans, K. & Aerts, J.

  1/10/10 → 30/09/11

  Project: Fundamental

  • cancer 100%
  • regulation 96%
  • quality of life 43%
  • funding 37%

• HERC10: Fluorescence activated cell sorter for immunobiolgical applications.

  Thielemans, K., Vanderkerken, K., Van Valckenborgh, E. & Aerts, J.

  22/07/10 → 21/07/15

  Project: Fundamental

  • fluorescence 100%
  • cells 72%

• OZR1801: Mechanisms responsible for dysfunction of cytotoxic T lymfocytes in patients infected with HIV-1.

  Aerts, J.

  1/01/09 → 31/12/10

  Project: Fundamental

  • Viruses 100%
  • T-Lymphocytes 37%
  • Helper-Inducer T-Lymphocytes 31%
  • HIV Infections 26%
  • Vaccination 23%

• OZR1612: Wederzijdse interacties tussen CD4+CD25+ regulatorische T cellen en myeloide dendritische cellen en hun impact op anti-tumorvaccinaties gebaseerd op dendritische cellen.

  Aerts, J.

  1/01/08 → 31/12/08

  Project: Fundamental

• FWOKN192: Wederzijdse interacties tussen CD4+CD25+ regulatorische T cellen en myeloï de dendritische cellen en hun impact op anti-tumorvaccinaties gebaseerd op dendritische cellen.

  Thielemans, K. & Aerts, J.

  1/01/08 → 31/12/08

  Project: Fundamental

• FWOTM400: Reciprocal interactions between CD4+CD25+ regulatory T cells and myeloid dendritic cells and their impact on dendritic cell based anti-tumor vaccinations

  Aerts, J.

  1/10/06 → 30/09/12

  Project: Fundamental

  • Dendritic Cells 100%
  • Regulatory T-Lymphocytes 67%
  • Myeloid Cells 63%
  • Vaccination 49%
  • Neoplasms 30%

• DWTC142: Terugkeermandaat Dr. Joeri AERTS : The role of cross-presentation in the processing and presentation of MHC class I restricted tumor antigens.

  Aerts, J. & Thielemans, K.

  1/10/04 → 30/09/06

  Project: Fundamental